| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Ledipasvir/sofosbuvir |
| Brand | Harvoni® |
| Indication | For the treatment of Chronic Hepatitis C (CHC) infection (Genotye 1, 3 and 4) in adults. |
| Assessment Process | |
| Rapid review commissioned | 14/11/2014 |
| Rapid review completed | 18/12/2014 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 18/03/2015 |
| NCPE assessment completed | 20/11/2015 |
| NCPE assessment outcome | Reimbursement Recommended for Genotype 1 and 4. |
